P-gp inhibitor 21
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity.
For research use only. We do not sell to patients.
- Formula: C27H42N2O4
- Molecular Weight:458.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI/ADR-RES | IC50 |
27.9 nM
Compound: 56
|
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation by measuring VNR IC50 at 10 uM incubated for 72 hrs in presence of VNR by SRB assay
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation by measuring VNR IC50 at 10 uM incubated for 72 hrs in presence of VNR by SRB assay
|
[PMID: 38502936] |
| NCI/ADR-RES | IC50 |
56.9 nM
Compound: 56
|
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation by measuring PTX IC50 at 10 uM incubated for 72 hrs in presence of PTX by SRB assay
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation by measuring PTX IC50 at 10 uM incubated for 72 hrs in presence of PTX by SRB assay
|
[PMID: 38502936] |
| NCI/ADR-RES | IC50 |
767.3 nM
Compound: 56
|
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation by measuring ADR IC50 at 10 uM incubated for 72 hrs in presence of ADR by SRB assay
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation by measuring ADR IC50 at 10 uM incubated for 72 hrs in presence of ADR by SRB assay
|
[PMID: 38502936] |
In Vitro
P-gp inhibitor 21 inhibits proliferations of cells KBV200 and NCI/ADR-RES (combined with VNR) with IC50s of 2.4 and 27.9 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Pharmacokinetic Analysis of P-gp inhibitor 21 in mice[1]
| route | Dose (mg/kg) | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUClast (ng·h/mL) | AUCinf_obs (ng·h/mL) | CLobs (mL/min/kg) | MRTinf_obs (h) | Vss (mL/kg) | F (%) |
| iv | 1 | - | - | 1260 | 1263 | 33.5 | 0.75 | 1528 | - | |
| po | 30 | 0.25 | 34.4 | 32.3 | 43.4 | - | 3.11 | - | 0.09 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KBV200 xenograft BALB/c nude mice[1]
-
Dosage:75 mg/kg
-
Administration:i.p.
-
Result:Suppressed tumor growth without significant body weight loss.
Chemical Information
-
Molecular Weight 458.63
-
Formula C27H42N2O4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)